ISSN 1742-5255, 1744-7607
9 papers in the library · 270 citations · publishing 2008-2026
Expert Opinion on Drug Metabolism & Toxicology May 4, 2026 Shreya Vasudeva, Gabrielle F. M. Lovell, Joshua Daniel Rosenblat
1. Esketamine nasal spray was FDA-approved in 2019 for treatment-resistant depression (TRD; in conjunction with an oral antidepressant), with approval expanded to major depressive disorder (MDD) wi...
Expert Opinion on Drug Metabolism & Toxicology 2026 Yang Jing Zheng, Christine E. Dri, Sabrina Wong et al.
Dextromethorphan/Buproprion (DXM/BUP) has received breakthrough FDA approval in August 2022 as a rapid-acting antidepressant. DXM/BUP is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, with bupropion (BUP), a norepinephrine/dopamine reuptake inhibitor and cytochrome P450 2D6 (CYP2D6) inhibitor. As DXM/BUP moves closer to widespread clinical use for...
Expert Opinion on Drug Metabolism & Toxicology August 19, 2025 Alice Caulfield, Elliot Hampsey, Allan H. Young
1. Classical psychedelics are gaining attention as potential treatments for a range of neuropsychiatric conditions, including depression, anxiety, and addictions [1]. Psychedelics differ from tradi...
Expert Opinion on Drug Metabolism & Toxicology December 2, 2022 Jérémy Carlier, Sara Malaca, Marilyn A. Huestis et al.
ABSTRACT Background 4-Hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) is a psychedelic tryptamine whose use is regulated in several countries. Due to unspecific effects, consumption can be ascertained only through toxicological analyses. However, the trace amounts of tryptamines are usually challenging to detect in biological samples. 4-OH-MPT metabolism was characterized to identify optimal...
Expert Opinion on Drug Metabolism & Toxicology June 18, 2021 M. Luz, Deborah C. Mash 30 citations
Ibogaine is a psychoactive indole alkaloid isolated from the West African shrub Tabernanthe iboga. It has been used by indigenous cultures to combat fatigue, hunger, and thirst, and to induce hallucinations during religious ceremonies. First isolated in 1901, ibogaine was initially recommended for use in asthenia at doses of 10 to 30 mg per day [1,2]. Semi-synthetic ibogaine came into use in...
Expert Opinion on Drug Metabolism & Toxicology March 31, 2020 Esther Papaseit, Clara Pérez‐mañá, Marta Torrens et al. 34 citations
Introduction: MDMA (3,4-methylenedioxymethamphetamine), a synthetic ring-substituted amphetamine, has become one of the most widely used recreational psychostimulant drugs in the world. Among recreational ecstasy/MDMA users, polydrug use is a phenomenon whose common purpose is to experience the synergistic effect of the combined drugs, moderate MDMA effects, prevent potential toxicity, enhance...
Expert Opinion on Drug Metabolism & Toxicology January 5, 2018 Esther Papaseit, Marta Torrens, Clara Pérez‐mañá et al. 20 citations
MDMA, 3,4-methylenedioxymethamphetamine, is a synthetic phenethylamine derivative with structural and pharmacological similarities to both amphetamines and mescaline. MDMA produces characteristic amphetamine-like actions (euphoria, well-being), increases empathy, and induces pro-social effects that seem to motivate its recreational consumption and provide a basis for its potential therapeutic...
Expert Opinion on Drug Metabolism & Toxicology April 4, 2013 Graham Lappin, Robert J. Noveck, Tal Burt 97 citations
INTRODUCTION: Microdosing is an approach to early drug development where exploratory pharmacokinetic data are acquired in humans using inherently safe sub-pharmacologic doses of drug. The first publication of microdose data was 10 years ago and this review comprehensively explores the microdose concept from conception, over the past decade, up until the current date. AREAS COVERED: The authors...
Expert Opinion on Drug Metabolism & Toxicology November 28, 2008 Graham Lappin, R Colin Garner 89 citations
BACKGROUND: Microdosing studies (human Phase 0) are used to select drug candidates for Phase I clinical trials on the basis of their pharmacokinetic properties, using subpharmacologic doses (maximum 100 microg). There are questions as to whether pharmacokinetic data obtained at these low doses will predict those at the clinically relevant dose. OBJECTIVE: To review the current literature on...